To compare the efficacy and safty of ABC-14 regimen with the traditional "3+7" regimen or AB-14 regimen in the treatment of newly diagnosed acute myeloid leukaemia
Diagnosed with AML (the diagnostic criteria refer to WHO2022 standard, non-APL), and have not received systemic anti-leukemia therapy (except hydroxyurea, low-dose cytarabine and other tumor reduction pretreatments);
Age ≥18 years old;
ECOG≤4;
The fertile woman agrees to use effective contraception during the treatment period and up to 3 months after the end of the treatment; Sign the informed consent form.
Known history of allergy to the investigational drug;
Resistance to azacytidine, azacitidine, Venetoclax;
Inability to take oral medication;
Combined with uncontrolled active infections (including bacterial, fungal or viral infections);